Table 3.
Prespecified maternal antenatal outcomes in women with BMI ≥25 at trial entry by treatment group. Values are numbers (%) of women and treatment effects are relative risks based on imputed data unless otherwise indicated
| Outcome | Lifestyle advice (n=1080*) | Standard care (n=1073*) | Treatment effect (95% CI), P value | |
|---|---|---|---|---|
| Hypertension | 101 (9) | 94 (9) | 1.06 (0.81 to 1.39), 0.65 | 1.05 (0.81 to 1.38), 0.70 |
| Pre-eclampsia | 56 (5) | 53 (5) | 1.05 (0.73 to 1.51), 0.80 | 1.03 (0.71 to 1.47), 0.89 |
| Gestational diabetes | 148 (14) | 120 (11) | 1.22 (0.97 to 1.54), 0.09 | 1.21 (0.96 to 1.52), 0.11 |
| Antenatal admission | 166 (15) | 191 (18) | 0.86 (0.71 to 1.04), 0.13 | 0.86 (0.71 to 1.04), 0.13 |
| Mean (SD) antenatal length of stay*‡ | 0.58 (2.11) | 0.85 (3.05) | 0.68 (0.50 to 0.93), 0.02 | 0.70 (0.51 to 0.95), 0.02 |
| Antepartum haemorrhage requiring admission | 16 (1.5) | 16 (1.5) | 0.99 (0.50 to 1.97), 0.98 | 1.00 (0.50 to 1.98), 0.99 |
| Preterm prelabour ruptured membranes | 9 (0.8) | 19 (1.8) | 0.47 (0.21 to 1.03), 0.06 | NA |
| Prelabour ruptured membranes at term | 9 (0.8) | 9 (0.9) | 0.99 (0.39 to 2.48), 0.98 | NA |
NA=not applicable.
*Includes all women who had liveborn or stillborn infant.
†Adjusted analyses included stratification variables BMI category, parity, and centre.
‡Treatment effects are ratios of means based on imputed data.